Tests semaglutide after pregnancy in people with recent gestational diabetes
Tests a weekly injection in postpartum adults with recent gestational diabetes.
Plain-language title generated from the registry record
Registry title: Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
Key facts
- Where
- Worcester, United StatesSee the site
- Phase
- Phase 2/3
Where in United States
- UMass MemorialWorcester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Massachusetts, Worcester
- Trial code
- NCT07797036
- Record updated
- 28 September 2026
- Original description
This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM will be randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, will be assessed at 6 months postpartum. Participants will subsequently enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation will reflect patient preferences, clinical decision-making, medication access, and insurance coverage.Read full original descriptionShow less
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial
This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM will be randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, will be assessed at 6 months postpartum. Participants will subsequently enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation will reflect patient preferences, clinical decision-making, medication access, and insurance coverage.
Inclusion: Age greater than or equal to 18; Postpartum state (delivered within 6 weeks); Ability and willingness to provide informed consent.
Exclusion: Known allergy to semaglutide from prior exposure; Previous participation in this trial; a history of acute or chronic pancreatitis; personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma; diagnosis of pre-gestational diabetes (type 1 or 2 diabetes mellitus); History of suicidal ideation/attempt in the past 12 months; Current or recent diagnosis in the last 12 months of anorexia nervosa, bulimia nervosa, binge eating disorder, or other eating disorder; body mass index <25 kg/m2; Plan to attempt pregnancy within next 12 months or confirmed pregnancy; Actively breastfeeding or lactating.